✦ LIBER ✦

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors

✍ Scribed by E. M. Newman; Mary Carroll; Steven A. Akman; Warren Chow; P. Coluzzi; Victor Hamasaki; Lucille A. Leong; Kim A. Margolin; Robert J. Morgan; James W. Raschko; Stephen Shibata; George Somlo; Merry Tetef; Y. Yen; Chul W. Ahn; James H. Doroshow

Publisher: Springer
Year: 1996
Tongue: English
Weight: 118 KB
Volume: 39
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800050569

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Initial clinical trial and pharmacokinet

Initial clinical trial and pharmacokinetics of ThymitaqTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors

✍ Patrick J. Creaven; Lakshmi Pendyala; Neal J. Meropol; Neil J. Clendeninn; Ellen 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 135 KB

Safety and pharmacokinetics of panitumum

Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors

✍ Toshihiko Doi; Atsushi Ohtsu; Makoto Tahara; Tomohide Tamura; Kuniaki Shirao; Ya 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 284 KB

Pharmacokinetic evaluation of high-dose

Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors

✍ W. Kreis; Daniel R. Budman; Vincent Vinciguerra; Kathleen Hock; Joann Baer; Rich 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 196 KB

Phase I study of a 120-hour continuous i

Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: A pediatric oncology group study

✍ Green, Daniel M. ;Krischer, Jeffrey P. ;Bell, Beverly ;Brecher, Martin L. ;Cushi 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

## Abstract To determine the maximum tolerated dose of 5‐fluorouracil administered as a 120‐hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m^2^/day. The maximum tolerated dosage (MTD) was 1,100 mg/m^2^/day. At this dosage l

Phase 1 pharmacokinetic and drug-interac

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

✍ Faye M. Johnson; Shruti Agrawal; Howard Burris; Lee Rosen; Navneet Dhillon; Davi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 1 views

Phase I clinical trial and pharmacokinet

Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors

✍ Charles L. Vogel; Elizabeth Gorowski; Enrique Davila; Mario Eisenberger; James K 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 823 KB

ICRF-187 was given to 62 evaluable patients with advanced solid tumors in a Phase I clinical trial. Weekly infusions were given in dosages ranging from 0.85 g/m2 to 7.42 g/m2 for a total of four weeks with a two week rest period between courses. Dose-limiting hematological toxicity was seen in heavi